Contact
searchSearch
HMP Global
Login
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
GLP-1 Receptor Agonists Linked to Lower Mortality and Thrombotic Complications in Essential Thrombocythemia
09/15/2026
Emily Estrada
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated GLP-1 receptor agonist use with improved survival and lower rates of thrombotic, cardiovascular, and infectious complications among patients with essential thrombocythemia, supporting prospective investigation...
Real-world findings associated...
09/15/2026
Oncology
News
Sustained Ropeginterferon Alfa-2b Treatment Deepens Molecular Responses in High-Risk Essential Thrombocythemia
09/15/2026
Emily Estrada
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase 3 SURPASS-ET trial showed that ropeginterferon alfa-2b provided durable hematologic responses and progressively reduced JAK2 V617F variant allele frequency in patients with high-risk essential thrombocythemia,...
Extended results from the phase...
09/15/2026
Oncology
News
Ropeginterferon Alfa-2b Achieves Increasing Complete Hematologic Response Rates With Longer Treatment in Patients With Myeloproliferative Neoplasms
09/15/2026
Emily Estrada
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study demonstrated that ropeginterferon alfa-2b produced increasing complete hematologic responses over time in patients with myeloproliferative neoplasms, including essential thrombocythemia, with tolerability...
Results from a real-world study...
09/15/2026
Oncology
News
Real-World Study Links Hyperlipidemia With Thrombosis in Essential Thrombocythemia
09/15/2026
Stephanie Holland
Real-world findings suggest that cardiovascular comorbidities, particularly hyperlipidemia and potentially hypertension, may contribute to thrombotic risk in essential thrombocythemia beyond conventional disease-related factors, supporting...
Real-world findings suggest that cardiovascular comorbidities, particularly hyperlipidemia and potentially hypertension, may contribute to thrombotic risk in essential thrombocythemia beyond conventional disease-related factors, supporting...
Real-world findings suggest that...
09/15/2026
Oncology
News
Mutant CALR-Targeted INCA033989 Shows Promising Activity in Treatment-Resistant Essential Thrombocythemia
09/15/2026
Stephanie Holland
INCA033989 demonstrated rapid and durable hematologic responses with molecular evidence of reduced mutant CALR burden in patients with CALR-mutant essential thrombocythemia resistant or intolerant to cytoreductive therapy, supporting further...
INCA033989 demonstrated rapid and durable hematologic responses with molecular evidence of reduced mutant CALR burden in patients with CALR-mutant essential thrombocythemia resistant or intolerant to cytoreductive therapy, supporting further...
INCA033989 demonstrated rapid...
09/15/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology
Guillermo Garcia-Manero, MD
Conference Coverage
Analyzing Management and Treatment Options for Patients With High-Risk MDS
10/08/2024
Guillermo Garcia-Manero, MD
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options for patients with high-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/08/2024
Oncology
Guillermo Garcia-Manero, MD
Conference Coverage
Examining Current and Upcoming Treatment Options for Patients With Low-Risk MDS
10/04/2024
Guillermo Garcia-Manero, MD
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting, Guillermo Garcia-Manero, MD, shared expert insight into treatment options that are available and upcoming for patients with low-risk myelodysplastic syndrome.
At the 2024 SOHO meeting,...
10/04/2024
Oncology
Dimopoulos
Conference Coverage
Advancing Treatment Options for High-Risk Multiple Myeloma
10/02/2024
Meletios-Athanasios Dimopoulos
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of...
10/02/2024
First Report Managed Care
Kerry Rogers, MD
Conference Coverage
Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?
09/23/2024
Kerry Rogers, MD
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry...
09/23/2024
Oncology
Prithviraj Bose, MD
Conference Coverage
Strategic Treatment Regimens Utilizing Approved JAK Inhibitors for Patients With Myelofibrosis
09/17/2024
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.
At the 2024 SOHO meeting,...
09/17/2024
Oncology
Conference Coverage
SOHO 2024 Insights: Examining the Use and Cost of Interferon Therapy for MPNs
09/13/2024
Amber Denham
In this interview, a leading expert discusses myeloproliferative neoplasms, as presented at the SOHO annual conference. Explore the interview to gain key insights into interferon therapies and important considerations for payers regarding...
In this interview, a leading expert discusses myeloproliferative neoplasms, as presented at the SOHO annual conference. Explore the interview to gain key insights into interferon therapies and important considerations for payers regarding...
In this interview, a leading...
09/13/2024
First Report Managed Care
Marion Subklewe, MD
Conference Coverage
The “ABCs” of Immunotherapy for Patients With Acute Myeloid Leukemia
09/06/2024
At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.
At the 2024 SOHO meeting, Marion Subklewe, MD, discusses the current landscape and future development of immune and cellular therapies for patients with acute myeloid leukemia.
At the 2024 SOHO meeting, Marion...
09/06/2024
Oncology
Pinkal Desai, MD
Conference Coverage
Challenges of Treating Secondary Acute Myeloid Leukemia With Standard Therapies
09/05/2024
Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.
Pinkal Desai, MD discusses the challenges of existing treatment options for patients with secondary acute myeloid leukemia and the need for further development of therapies for this disease subset.
Pinkal Desai, MD discusses the...
09/05/2024
Oncology
Abdulraheem Yacoub, MD
Conference Coverage
Developments in Utilizing Interferons for the Treatment of Myeloproliferative Neoplasms
09/04/2024
Abdulraheem Yacoub, MD
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares expert insight into the use of interferons for the treatment of patients with myelofibrosis, essential thrombocythemia, and polycythemia vera.
Abdulraheem Yacoub, MD, shares...
09/04/2024
Oncology
Eduardo Rego, MD, PhD
Conference Coverage
Exploring Developments and Challenges of Immunological Approaches in AML Treatment
09/04/2024
Eduardo Rego, MD, PhD
At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.
At the 2024 Society of Hematologic Oncology meeting, Eduardo Rego, MD, shares his interest in reviewing data on novel research in acute myeloid leukemia treatment development, specifically the incorporation of immunological approaches.
At the 2024 Society of...
09/04/2024
Oncology
Eduardo Rego, MD, PhD
Conference Coverage
Analyzing Data on the Improvement of International Outcomes of Acute Myeloid Leukemia Therapy
09/04/2024
Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...
Eduardo Rego, MD, shares expert insight into International Consortium on Acute Leukemia research on improving the outcomes of therapy for patients with AML treated in Latin America compared to the outcomes of those treated in the US and...
Eduardo Rego, MD, shares expert...
09/04/2024
Oncology

The annual Society of Hematologic Oncology (SOHO) Meeting focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies with insights from internationally recognized experts.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use